Article 1

Delegated Regulation (EU) No 877/2013 is amended as follows:

(1)

Article 1 is replaced by the following:

Article 1Subject matter

This Regulation lays down specifications concerning the content of the reports that Member States whose currency is the euro are required to submit pursuant to Article 10(3) of Regulation (EU) No 473/2013.

;

(2)

the following new Article 2a is inserted:

Article 2aStructure and content of the reporting of Member States under enhanced surveillance pursuant to Article 2(3) and (4) of Regulation (EU) No 472/2013 as a result of having drawn on the Pandemic Crisis Support of the European Stability Mechanism1.

Where a Member State is subject to enhanced surveillance solely as a result of having drawn on the Pandemic Crisis Support of the European Stability Mechanism, the in-year reporting requirement pursuant to Article 10 of Regulation (EU) No 473/2013 shall pertain to the use of the Pandemic Crisis Support funds to cover direct and indirect healthcare, cure and prevention-related costs related to the COVID-19 pandemic.

The reports shall include the table indicated in Annex II.

;

(3)

the title of the Annex is replaced by the following:

ANNEX I

;

(4)

the following new Annex II is added:

ANNEX IITable to be transmitted quarterlyCosts related to the COVID-19 pandemic
Year 2020
Year 2021
The last year of the availability period or of a possible disbursement of the Pandemic Crisis Support (whichever is earlier) is also the last year of the reporting, unless the Member State has not yet used all the funds drawn.
In EUR millionTime series of actual data ending at quarter of the respective report to be submitted
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Healthcare, cure and prevention costs directly related to the COVID-19 pandemic
[Item]
[Further items as necessary]
Items and sub-items, as necessary, accompanied with the relevant explanations to allow the Commission to perform a meaningful assessment.
Part of overall public healthcare spending estimated to be directly or indirectly attributed to addressing the impact of COVID-19 on the healthcare system
This can include, inter alia, spending on hospitals; cure and rehabilitative care, ambulatory cure and rehabilitative care, diagnostics, pharmaceuticals, preventive care, health administrations, and health related long-term care.
[Item]
[Further items as necessary]
Other indirect costs related to healthcare, cure and prevention due to the COVID-19 crisis
[Item]
[Further items as necessary]

	Year 2020				Year 2021 The last year of the availability period or of a possible disbursement of the Pandemic Crisis Support (whichever is earlier) is also the last year of the reporting, unless the Member State has not yet used all the funds drawn.
In EUR millionTime series of actual data ending at quarter of the respective report to be submitted	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Healthcare, cure and prevention costs directly related to the COVID-19 pandemic
[Item]
[Further items as necessary] Items and sub-items, as necessary, accompanied with the relevant explanations to allow the Commission to perform a meaningful assessment.
Part of overall public healthcare spending estimated to be directly or indirectly attributed to addressing the impact of COVID-19 on the healthcare system This can include, inter alia, spending on hospitals; cure and rehabilitative care, ambulatory cure and rehabilitative care, diagnostics, pharmaceuticals, preventive care, health administrations, and health related long-term care.
[Item]
[Further items as necessary]
Other indirect costs related to healthcare, cure and prevention due to the COVID-19 crisis
[Item]
[Further items as necessary]